Details of the Drug
General Information of Drug (ID: DMFIS4D)
Drug Name |
MCD-386
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
CDD-0102; CDD-0262; CDD-0264; CDD-102; MCD-386 Forte; MCD-386 Transderm; MCD-386CR; MCD-386 Forte/Transderm; Tetrahydropyrimidine muscarinic M1 agonists (Alzeimer's disease), Cognitive Pharmaceuticals; Tetrahydropyrimidine muscarinic M1 agonists (Alzeimer's disease), University of Toledo; Tetrahydropyrimidine muscarinicM1 agonists (Alzheimer's disease), Mithridion; MCD-386 (oral controlled release, CNS disorders), Mithridion; MCD-386 (high dose transdermal, Alzheimer's disease/schizophrenia), Mithridion; MCD-386 (high dose, Alzheimer's disease/schizophrenia), Mithridion; MCD-386 (transdermal, Alzheimer's disease/schizophrenia), Mithridion
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Structure | 3D Structure is Not Available | ||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Combinatorial Drugs (CBD) | Click to Jump to the Detailed CBD Information of This Drug | ||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Alzheimer disease | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | 8A20 | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References